Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study

BACKGROUND: National and international guidelines recommend stopping migraine prophylaxis with CGRP(-receptor) monoclonal antibodies after 6–12 months of successful therapy. In this study, we aimed to analyze the course of migraine for four months after the cessation of CGRP(-receptor) antibodies us...

Descripción completa

Detalles Bibliográficos
Autores principales: Raffaelli, Bianca, Terhart, Maria, Overeem, Lucas Hendrik, Mecklenburg, Jasper, Neeb, Lars, Steinicke, Maureen, Reuter, Uwe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988461/
https://www.ncbi.nlm.nih.gov/pubmed/34579559
http://dx.doi.org/10.1177/03331024211046617

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988461/
https://www.ncbi.nlm.nih.gov/pubmed/34579559
http://dx.doi.org/10.1177/03331024211046617

Ejemplares similares